

	MPA-based (n=12)	mTORi-based (n=12)
Graft failure	0	0
Death	1/12 (8.3%)	1/12 (8.3%)
Creatinine (mg/dL)	1.76 ± 0.69	1.61 ± 0.90
Total number of renal biopsies	2.83 ± 1.94	2.75 ± 1.54
BPAR any grade	4/12 (33.3%)	2/12 (16.7%)
Subclinical rejection	1/4 (25.0%)	1/4 (25.0%)
Episodes of ABMR	3/12 (25.0%)	2/12 (16.7%)
Active ABMR	3/12 (31.6%)*	4/33 (12.1%)
- C4d positive	3/3 (100.0%)	2/2 (100.0%)
- Resolution after treatment	2/3 (66.6%)	2/2 (100.0%)
Chronic-active ABMR	0	0
Episodes of TCMR	2/12 (16.7%)	0
1a	0	0
1b	1/12 (8.3%)	0
2a	1/12 (8.3%)*	0
2b	0	0
3	0	0

Table S1 – Sub-group analysis of clinically relevant end-points at one year after kidney transplantation in patients with a positive flow-cytometry crossmatch or DSA before transplantation. *1 patient in the MPA group developed both ABMR and TCMR. Data is presented as absolute numbers and percentages or as mean ± standard deviation.

	MPA-based (n=38)	mTORi-based (n=33)	P- value
Triglycerides (mg/dL)	155.66 ± 73.23	187.12 ± 94.68	0.175
Total cholesterol (mg/dL)	184.07 ± 40.30	221.44 ± 57.53	0.007
LDL cholesterol (mg/dl)	105.68 ± 27.91	116.59 ± 37.09	0.241
NODAT (%)	6/38 (15.8%)	5/33 (15.2%)	0.941
CMV reactivation (%)	16/38 (42.1%)	9/33 (27.3%)	0.221
CMV disease (%)	3/38 (7.9%)	0	0.243
BK reactivation (%)	3/38 (7.9%)	0	0.243
BK nephropathy (%)	1/38 (2.6%)	0	1
Wound infection (%)	6/38 (15.8%)	1/33 (3.0%)	0.113
Lymphocele (%)	1/38 (2.6%)	3/33 (9.1%)	0.331
Proteinuria (mg/24hours)	321.39 ± 624.89	529.52 ± 708.71	0.240

Table S2 – Common side effects associated with immunosuppression at one year after kidney transplant. NODAT, New-Onset Diabetes After Transplantation. Data is presented as absolute numbers and percentages or as mean ± standard deviation.